Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

<p>Shows Phenotype, Viability, and Cytotoxicity of the Product.</p>

Сохранить в:

Библиографические подробности
Главный автор:	Ulka N. Vaishampayan (15051039) (author)
Другие авторы:	Archana Thakur (15051042) (author), Wei Chen (15051045) (author), Abhinav Deol (15051048) (author), Meera Patel (15051051) (author), Kimberlee Dobson (15051054) (author), Brenda Dickow (15051057) (author), Dana Schalk (15051060) (author), Amy Schienschang (15051063) (author), Sarah Whitaker (15051066) (author), Amanda Polend (15051069) (author), Joseph A. Fontana (411960) (author), Elisabeth I. Heath (15024674) (author), Lawrence G. Lum (15051072) (author)
Опубликовано:	2025
Предметы:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы